Marc A. Cohen - Jun 14, 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Director
Signature
/s/ Shoaib Ghias, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Jun 14, 2021
Transactions value $
$0
Form type
4
Date filed
6/14/2021, 05:16 PM
Next filing
Jun 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Other $0 +92.8K +1516.87% $0.00 98.9K Jun 14, 2021 Direct F1
transaction CCCC Common Stock Other $0 +22.6K +1.22% $0.00 1.87M Jun 14, 2021 See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the receipt of shares by the Reporting Person pursuant to pro rata distributions-in-kind, without consideration, of shares of the company's common stock effected on June 14, 2021 by Cobro Ventures Opportunity Fund, L.P. ("Cobro Ventures") to the partners of Cobro Ventures and by its general partner, Cobro Ventures Fund GP, LLC. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended.
F2 Shares held by Reporting Person as trustee of the Marc Andrew Cohen Revocable Trust. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.